Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Financing Activities (2023 - 2025)

CG Oncology's Cash from Financing Activities history spans 3 years, with the latest figure at $99.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 55.66% year-over-year to $99.1 million; the TTM value through Dec 2025 reached $153.6 million, down 75.55%, while the annual FY2025 figure was $153.6 million, 75.55% down from the prior year.
  • Cash from Financing Activities reached $99.1 million in Q4 2025 per CGON's latest filing, up from $54.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $402.7 million in Q1 2024 to a low of -$15.2 million in Q2 2023.
  • Average Cash from Financing Activities over 3 years is $72.4 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 52735.03% in 2024, then crashed 840.0% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at -$2.9 million in 2023, then soared by 7814.57% to $223.4 million in 2024, then tumbled by 55.66% to $99.1 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Cash from Financing Activities are $99.1 million (Q4 2025), $54.4 million (Q3 2025), and -$296000.0 (Q2 2025).